Pleiotropic functions of bile acids mediated by the farnesoid X receptor

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 4, 2012, Pages 389-398

  Stanimirov, Bojan ^a   Stankov, K ^a   Mikov, M ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Atherosclerosis; Cholestasis; Diabetes; Liver; Metabolism

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6 ETHYL CHENODEOXYCHOLIC ACID; BILE ACID; BILE ACID CONJUGATE; FARNESOID X RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CELL RECEPTOR; CHOLESTEROL; FARNESOID X-ACTIVATED RECEPTOR; GLUCOSE;

ALCOHOLIC FATTY LIVER; ATHEROSCLEROSIS; BILE ACID METABOLISM; CHOLESTASIS; CHOLESTEROL METABOLISM; DIABETES MELLITUS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIMARY BILIARY CIRRHOSIS; PROTEIN FUNCTION; REVIEW; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENTEROHEPATIC CIRCULATION; FAT INTAKE; LIVER CELL; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTASIS; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; DIETARY FATS; DRUG EVALUATION, PRECLINICAL; ENTEROHEPATIC CIRCULATION; GLUCOSE; HEPATOCYTES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

MLCS; MLOWN;

EID: 84875034795     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. THOMAS C., PELLICCIARI R., PRUZANSKI M., AUWERX J., SCHOONJANS K. Targeting bileacid signalling for metabolic diseases. Nat. Rev. Drug Discov., 2008, 7: 678-693.
2. BISHOP-BAILEY D., WALSH DT., WARNER TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. USA, 2004, 101: 3668-3673.
3. TRAUNER M., CLAUDEL T., FICKERT P., MOUSTAFA T., WAGNER M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis., 2010, 28: 220-224.
4. WANG H., CHEN J., HOLLISTER K., SOWERS LC., FORMAN BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell., 1999, 3: 543-553.
5. MODICA S., GADALETA R.M., MOSCHETTA A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal., 2010, 8: e005.
6. HUBER R.M., MURPHY K., MIAO B., LINK J.R., CUNNINGHAM M.R., RUPAR M.J. et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene., 2002, 290: 35-43.
7. PELLICCIARI R., COSTANTINO G., FIORUCCI S. Farnesoid X receptor: form structure to potential clinical applications. J. Med. Chem., 2005, 48: 5383-5403.
8. MAKISHIMA M., OKAMOTO A.Y., REPA J.J., TU H., LEARNED R.M., LUK A. et al. Identification of a nuclear receptor for bile acids. Science, 1999, 284: 1362-1365.
9. PARKS D.J., BLANCHARD S.G., BLEDSOE R.K., CHANDRA G., CONSLER T.G., KLIEWER S.A. et al. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284: 1365-1368.
10. SWANN J.R., WANT E.J., GEIER F.M., SPAGOU K., WILSON I.D., SIDAWAY J.E. et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. USA, 2011; 108 Suppl. 1: 4523-30.
11. LEFEBVRE P., CARIOU B., LIEN F., KUIPERS F., STAELS B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev., 2009, 89: 147-191.
12. FIORUCCI S., MENCARELLI A., DISTRUTTI E., PALLADINO G., CIPRIANI S. Targetting Farnesoid-X-receptor from medicinal chemistry to disease treatment. Curr. Med. Chem. Curr. Med. Chem., 2010, 17: 139-159.
13. PELLICCIARI R., FIORUCCI S., CAMAIONI E., CLERICI C., COSTANTINO G., MALONEY P.R. et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anti-cholestatic activity. J. Med. Chem., 2002, 45: 3569-3572.
14. MASON A., LUKETIC V., LINDOR K., HIRSCHFIELD G., GORDON S., MAYO M. et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J. Hepatol., 2010; 52 (Suppl 1): S1-S2.
15. SANYAL A.J., MUDALIAR R.R., HENRY R.R., MARSCHALL H.U., MORROW L., SCIACCA C.I. et al. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study. Hepatology, 2009, 50: 389-390.
16. FIORUCCI S., RIZZO G., DONINI A., DISTRUTTI E., SANTUCCI L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med., 2007, 13: 298-309.
17. LU T.T., MAKISHIMA M., REPA J.J., SCHOONJANS K., KERR T.A., AUWERX J. et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell., 2000, 6: 507-515.
18. CHANDA D., PARK J.H., CHOI H.S. Molecular basis of endocrine regulation by orphan nuclear receptor small heterodimer partner. Endocr. J., 2008, 55: 253-268.
19. MALONEY P.R., WILLSON T.M., KLIEWER S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell., 2000, 6: 517-526.
20. ZHANG M., CHIANG Y.J. Transcriptional regulation of the human sterol 12 alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J. Biol. Chem., 2001, 276: 41690-41699.
21. INAGAKI T., CHOI M., MOSCHETTA A., PENG L., CUMMINS C.L., MC DONALD J.G. et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab., 2005, 2: 217-225.
22. SCHAAP F.G., VAN DER GAAG N.A., GOUMA D.J., JANSEN P.L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology, 2009, 49: 1228-1235.
23. STRACK A.M., MYERS R.W. Modulation of metabolic syndrome by fibro-blast growth factor 19 (FGF19)? Endocrinology, 2004, 145: 2591-2593.
24. PIRCHER P.C., KITTO J.L., PETROWSKI M.L., TANGIRALA R.K., BISCHOFF E.D., SCHULMAN I.G. et al. Farnesoid X receptor regulates bile acid-amino conjugation. J. Biol. Chem., 2003, 278: 27703-27711.
25. ANANTHANARAYANAN M., BALASUBRAMANIAN N.V., MAKISHIMA M., MANGELSDORF D.J., SUCHY F.J. Human bile salt export pump (BSEP) promoter is transactivated by the farnesoid X receptor/bile acid receptor (FXR/BAR). J. Biol. Chem., 2001, 276: 28857-28865.
26. KAST H.R., GOODWIN B., TARR P.T., JONES S.A., ANISFELD A.M., STOLTZ C.M. et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid Xactivated receptor, and constitutive androstane receptor. J. Biol. Chem., 2002, 277: 2908-2915.
27. STRAUTNIEKS S.S., BULL L.N., KNISELY A.S., KOCOSHIS S.A., DAHL N., ARNELL H. et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet., 1998, 20: 233-238.
28. DE VREE J.M., JACQUEMIN E., STURM E., CRESTEIL D., BOSMA P.J., ATEN J. et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. USA, 1998, 95: 282-287.
29. BOYER J.L., TRAUNER M., MENNONE A., SOROKA C.J., CAI S.Y., MOUSTAFA T. et al. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST α /OST β in cholestasis in humans and rodents. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290: 1124-1130.
30. CHEN F., MA L., DAWSON P.A., SINAL C.J., SEHAYEK E., GONZALEZ F.J. et al. Liver receptor homologue-1 mediates species-and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem., 2003, 278: 19909-19916.
31. BALLATORI N., CHRISTIAN W.V., LEE J.Y., DAWSON P.A., SOROKA C.J., BOYER J.L. et al. OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology, 2005, 42: 1270-1279.
32. CLAUDEL T., ZOLLNER G., WAGNER M., TRAUNER T. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochim. Biophys. Acta, 2011, 1812: 867-878.
33. GNERRE C., BLATTLER S., KAUFMANN M.R., LOOSER R., MEYER U.A. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmaco-genetics, 2004, 14: 635-645.
34. SONG C.S., ECHCHGADDA I., BAEK B.S., AHN S.C., OH T., ROY A.K. et al. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem., 2001, 276: 42549-42556.
35. BARBIER O., TORRA I.P., SIRVENT A., CLAUDEL T., BLANQUART C., DURAN-SANDOVAL D. et al. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology, 2003, 124: 1926-1940.
36. SCHOENFIELD L.J., LACHIN J.M. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the national cooperative gallstone study. A controlled trial of efficacy and safety. Ann. Intern. Med., 1981, 95: 257-282.
37. NAKAHARA M., FUJII H., MALONEY P.R., SHIMIZU M., SATO R. Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA. J. Biol. Chem., 2002, 277: 37229-37234.
38. LEISS O., VON BERGMANN K. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol., 1982, 17: 587-592.
39. VAN DER STEEG W.A., HOLME I., BOEKHOLDT S.M., LARSEN M.L., LINDAHL C., STROES E.S. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., 2008, 51: 634-642.
40. HAGEMAN J., HERREMA H., GROEN K.A., KUIPERS F. A role of the bile salt receptor FXR in atherosclerosis. Atheroscler. Thromb. Vasc. Biol., 2010, 30: 1519-1528.
41. SHIH D.M., KAST-WOELBERN H.R., WONG J., XIA Y.R., EDWARDS P.A., LUSIS A.J. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J. Lipid Res., 2006, 47: 384-392.
42. URIZAR N.L., DOWHAN D.H., MOORE D.D. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem., 2000, 275: 39313-39317.
43. MENCARELLI A., FIORUCCI S. FXR an emerging target for the treatment of atherosclerosis. J. Cell. Mol. Med., 2010, 14: 79-92.
44. HE F., LI J., MU Y., KURUBA R., MA Z., WILSON A. et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res., 2006, 98: 192-199.
45. LI J., WILSON A., KURUBA R., ZHANG Q., GAO X., HE F. et al. FXRmediated regulation of enos expression in vascular endothelial cells. Cardio-vasc. Res., 2008, 77: 169-177.
46. RENGA B., MENCARELLI A., MIGLIORATI M., DISTRUTTI E., FIORUCCI S. Bile-acid-activated farnesoid x receptor regulates hydrogen sulfide production and hepatic microcirculation. World. J. Gastroenterol., 2009, 15: 2097-2108.
47. LI Y.T., SWALES K.E., THOMAS G.J., WARNER T.D., BISHOPBAILEY D. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol., 2007, 27: 2606-2611.
48. QIN P., TANG X., ELLOSO M.M., HARNISH D.C. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am. J. Physiol. Heart Circ. Physiol., 2006, 291: 741-747.
49. BELL G.D. Serum lipids in cholelithiasis: effect of chenodeoxycholic acid therapy. BMJ, 1973, 3: 520-523.
50. MILLER N.E., NESTEL P.J. Triglyceride-lowering effect of chemodeoxycholic acid in patients with endogenous hypertriglyceridemia. Lancet, 1974, 2: 929-31.
51. WATANABE M., HOUTEN S.M., WANG L., MOSCHETTA A., MANGELSDORF D.J., HEYMAN R.A. et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest., 2004, 113: 1408-1418.
52. KAST H.R., NGUYEN C.M., SINAL C.J., JONES S.A., LAFFITTE B.A., REUE K. et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol., 2001, 15: 1720-1728.
53. CLAUDEL T., INOUE Y., BARBIER O., DURAN-SANDOVAL D., KOSYKH V., FRUCHART J. et al. Farnesoid X receptor agonists supress hepatic apolipoprotein CIII expression. Gastroenterology, 2003, 125: 544-555.
54. SIRVENT A., CLAUDEL T., MARTIN G., BROZEK J., KOSYKH V., DARTEIL R. et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett., 2004, 566: 173-177.
55. ZHANG Y., CASTELLANI L.W., SINAL C.J., GONZALEZ F.J., EDWARDS P.A. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev., 2004, 18: 157-169.
56. PRAWITT J., CARON S., STAELS B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr. Diab. Rep., 2011, 11: 160-166.
57. ZHANG Y., LEE F.Y., BARRERA G., LEE H., VALES C., GONZALES F.J. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA, 2006, 103: 1006-1011.
58. CIPRIANI S., MENCARELLI A., PALLADINO G., FIORUCCI S. FXR activation reverses insulin resistance and lipid anormalities and protect against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res., 2010, 51: 771-784.
59. CALKIN A.C., TONTONOZ P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell. Biol., 2012, 13: 213-224.
60. YAMAGATA K., DAITOKU H., SHIMAMOTO Y., MATSUZAKI H., HIROTA K., ISHIDA J. et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem., 2004, 279: 23158-23165.
61. POTTHOFF M., BONEY-MONTOYA J., CHOI M., HE T., SUNNY N.E., SATAPATI S. et al. Fgf15/19 regulates hepatic glucose metabolism by inhibiting the creb-pgc-1α pathway. Cell Metab., 2011, 13: 729-738.
62. ZHANG Y., LEE F.Y., BARRERA G., LEE H., VALES C., GONZALES F. et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA, 2006, 103: 1006-1011.
63. DURAN-SANDOVAL D., MAUTINO G., MARTIN G., PERCEVAULT F., BARBIER O., FRUCHART J.C. et al. Glucose regulates the expression if the farnesoid X receptor in liver. Diabetes, 2004, 53: 890-898.
64. STAYROOK K.R., BRAMLETT K.S., SAVKUR R.S., FICORILLI J., COOK T., CHRISTE M.E. et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology, 2005, 146: 984-991.
65. MA K., SAHA P.K., CHAN L., MOORE D.D. et al. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest., 2006, 116: 1102-1109.
66. KAHN S.E., HULL R.L., UTZSCHENEIDER K.M. Mechanism linking obesity to insulin resistance to insulin resistance and type 2 diabetes. Nature, 2006, 444: 840-846.
67. POPESCU I.R., HELLEBOID-CHAPMAN A., LUCAS A., VANDEWALLE B., DUMONT J., BOUCHAERT E. et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett., 2010, 584: 2845-2851.
68. ADORINI L., PRUZANSKI M., SHAPIRO D. Farnesoid X receptor targeting to treat nonalcocholic steatohepatitis. Drug Discov. Today, 2012, http://dx.doi.org/10.1016/j.drudis.2012.05.012.
69. RENGA B., MENCARELLI A., VAVASSORI P., BRANCALEONE V., FIORUCCI S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta, 2010, 1802: 363-372.
70. BEYSEN C., MURPHY E.J., DEINES K., CHAN M., TSANG E., GLASS A. et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia, 2012, 55: 432-442.
71. KATSUMA S., HIRASAWA A., TSUJIMOTO G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun., 2005, 329: 386-390.
72. OZCAN U., YILMAZ E., OZCAN L., FURUHASHI M., VAILLANCOURT E., SMITH R.O. et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 2006, 313: 1137-1140.
73. STANKOV K. Genetic predisposition for type 1 diabetes mellitus-the role of endoplasmic reticulum stress in human disease etiopathogenesis. J. Med. Biochem., 2010, 29: 139-149.
74. MIKOV M., FAWCETT J.P., KUHAJDA K., KEVRESAN S. Pharmacology of bile acids and their derivates: absorption promoters and therapeutic agents. Eur. J. Drug. Metab. Pharmacokinet., 2006, 31: 237-251.
75. MIKOV M., AL-SALAMI H., GOLOCORBIN-KON S., SKRBIC R., RASKOVIC A., FAWCETT J.P. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur. J. Drug. Metab. Pharmacokinet., 2008, 33: 137-142.
76. KOJIC-DAMJANOV S., DJERIC M., MIKOV M., KUHAJDA K., KEVRESAN S. Influence of sodium monoketocholate on the hypolipidemic activity of lovastatin in healthy and diabetic rats. Eur. J. Drug. Metab. Pharmacokinet., 2008, 33: 77-84.
77. RASKOVIC A., MIKOV M., SKRBIC R., JAKOVLJEVIC V., VASOVIC V., POSA M. et al. Effect of stevioside and sodium salt of monoketocholic acid on glycemia in normoglycemic and diabetic rats. Eur. J. Drug. Metab. Pharmacokinet., 2008, 33: 17-22.
78. MIKOV M., AL-SALAMI H., GOLOCORBIN KON S. Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. In: CHIH-PIN L. (ed). Type 1 diabetes-complications, pathogenesis and alternative treatments. USA: InTech., 2011: 365-402.
79. ROMA M.G., TOLEDO F.D., BOAGLIO A.C., BASIGLIO C.L., CROCENZI F.A., SÁNCHEZ POZZI E.J. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin. Sci. (Lond)., 2011, 121: 523-544.
80. ZOLLNER G., MARSCHALL H.U., WAGNER M., TRAUNER M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm., 2006, 3: 231-251.
81. LIU Y., BINZ J., NUMERICK M.J., DENNIS S., LUO G., DESAI B. et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis. J. Clin. Invest., 2003, 112: 1678-1687.
82. FIORUCCI S., CLERICI C., ANTONELLI E., ORLANDI S., GOODWIN B., SADEGHPOUR B.M. et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen induced cholestasis. J. Pharmacol. Exp. Ther., 2005, 313: 604-612.
83. ZOLLNER G., TRAUNER M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol., 2009, 156: 7-27.
84. FICKERT P., ZOLLNER G., FUCHSBICHLER A., STUMPTNER C., WEIGLEIN A.H., LAMMERT F. et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology, 2002, 123: 1238-1251.
85. GADALETA R.M., VAN MIL S.W., OLDENBURG B., SIERSEMA P.D., KLOMP L.W., VAN ERPECUM K.J. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim. Biophys. Acta, 2010, 1801: 683-692.
86. MODICA S., PETRUZZELLI M., BELLAFANTE E., MURZILLI S., SALVATORE L., CELLI N. et al. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastro-enterology, 2012, 142: 355-365.
87. WANG Y.D., CHEN W.D., WANG M., YU D., FORMAN B.M., HUANG W. Farnesoid X receptor antagonizes nuclear factor B in hepatic inflammatory response. Hepatology, 2008, 48: 1632-1643.
88. FIORUCCI S., RIZZO G., ANTONELLI E., RENGA B., MENCARELLI A., RICCARDI L. et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferatoractivated receptor gamma contributes to the anti-fibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther., 2005, 315: 58-68.
89. FICKERT P., FUCHSBICHLER A., MOUSTAFA T., WAGNER M., ZOLLNER G., HALILBASIC E. et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol., 2009, 175: 2392-2405.
90. LINDOR K.D. Farnesoid X receptor agonists for primary biliary cirrhosis. Curr. Opin. Gastroenterol., 2011, 27: 285-288.